Top

Published in:

Open Access 18-12-2024 | Human Immunodeficiency Virus | Substantive Review

Depressive Symptoms and HIV Viral Suppression: A Systematic Review and Meta-analysis

Authors: Bishan Huang, Alitasha Younger, Mary P. Gallant, Thomas J. O’Grady

Published in: AIDS and Behavior | Issue 3/2025

Abstract

Previous research suggests that depression impacts HIV outcomes, including viral suppression. This meta-analysis quantifies the association between depression and HIV viral suppression. A systematic literature search was conducted in PubMed, Web of Science, EBSCO, and OVID to identify studies published through 2012 to 2022. The software Rayyan was used to evaluate eligibility of studies, and the 2020 Preferred Reporting Items for Systematic Reviews and Meta-analysis guidelines were used for abstracting data. A random effects meta-analysis was performed using Review Manager 5.4.1. Of the 1911 articles screened, 16 studies were included covering 80,103 participants. The results showed individuals without depression were more likely to achieve HIV viral suppression or undetectable viral load compared to individuals with depression (OR 1.30; 95%CI 1.15, 1.48; I² = 76%). Subgroup analysis indicated this effect was significant among the general population of people living with HIV (n = 75,353; OR 1.32; 95%CI 1.12, 1.55; I² = 85%) and cisgender women living with HIV (n = 4553; OR 1.28; 95%CI 1.09, 1.50; I² = 16%), but not among cisgender men living with HIV (most identified as men who have sex with men) (n = 197; OR 2.13; 95%CI 0.43, 10.61; I² = 83%). This meta-analysis shows a significant positive association between the absence of depression and achieving HIV viral suppression overall and among the subgroup of cisgender women. Public health interventions for people living with HIV should include strategies to identify and address the depressive symptoms that impact adherence to treatment, increase the risk of psycho-behavioral co-morbidities, and exacerbate social or structural factors impeding viral suppression.

Available only for authorised users

World Health Organization. What’s new in treatment monitoring: viral load and CD4 testing [Internet]. 2017 [cited 2024 Sep 1]. Available from: https://www.who.int/publications/i/item/WHO-HIV-2017.22.

Waju B, Dube L, Ahmed M, Assefa SS. Unsuppressed viral load level in public health facilities: nonvirological predictors among adult antiretroviral therapy users in Southwestern Ethiopia. HIV/AIDS. 2021;13:513–26.

Anito AA, Lenjebo TL, Woticha E, Solomon F. Magnitude of viral load suppression and associated factors among clients on antiretroviral therapy in public hospitals of Hawassa City administration, Ethiopia. HIV/AIDS. 2022;14:529.

Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2021. Atlanta: Centers for Disease Control and Prevention; 2023.

HIV.gov. Ending the HIV epidemic [Internet]. 2019 [cited 2023 Aug 28]. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview/.

O’Grady T, Inman N, Younger A, Huang B, Bouton TO, Kim H, et al. The characteristics and HIV-related outcomes of people living with co-occurring HIV and mental health conditions in the United States: a systematic review of literature from 2016 to 2021. AIDS Behav. 2023;1:1–24. https://doi.org/10.1007/s10461-023-04150-9.CrossRef

HIV.gov. HIV & AIDS trends and U.S. statistics overview [Internet]. 2022 [cited 2023 Aug 28]. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics/.

Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725–30. https://doi.org/10.1176/appi.ajp.158.5.725.CrossRefPubMed

Rubin LH, Maki PM. HIV, depression, and cognitive impairment in the era of effective antiretroviral therapy. Curr HIV/AIDS Rep. 2019;16:82–95. https://doi.org/10.1007/s11904-019-00421-0.CrossRefPubMedPubMedCentral

10.

Perazzo JD, Currie J, Horvat Davey C, Lambert J, Webel AR. Depression and social capital in people living with HIV. J Psychiatr Nurs. 2020;27:54–61. https://doi.org/10.1111/jpm.12552.CrossRef

11.

Tesfaw G, Ayano G, Awoke T, Assefa D, Birhanu Z, Miheretie G, et al. Prevalence and correlates of depression and anxiety among patients with HIV on-follow up at Alert Hospital, Addis Ababa, Ethiopia. BMC Psychiatry. 2016. https://doi.org/10.1186/s12888-016-1037-9.CrossRefPubMedPubMedCentral

12.

Choi SKY, Boyle E, Cairney J, Collins EJ, Gardner S, Bacon J, et al. Prevalence, recurrence, and incidence of current depressive symptoms among people living with HIV in Ontario, Canada: results from the Ontario HIV Treatment Network Cohort Study. PLoS ONE. 2016;11: e0165816. https://doi.org/10.1371/journal.pone.0165816.CrossRefPubMedPubMedCentral

13.

Pence BW, Mills JC, Bengtson AM, Gaynes BN, Breger TL, Cook RL, et al. Association of increased chronicity of depression with HIV appointment attendance, treatment failure, and mortality among HIV-infected adults in the United States. JAMA Psychiatry. 2018;75:379–85.PubMedPubMedCentral

14.

Rosenthal MA, Wanje G, Richardson BA, Shafi J, Wang L, Masese L, et al. A prospective study of depressive symptoms, condomless sex, and HIV viral load in HIV-positive female sex workers in Kenya. AIDS Behav. 2021;25:3047–56.PubMedPubMedCentral

15.

Tran BX, Ho RCM, Ho CSH, Latkin CA, Phan HT, Ha GH, et al. Depression among patients with HIV/AIDS: research development and effective interventions (GAP research). Int J Environ Res Public Health. 2019;16:1772.PubMedPubMedCentral

16.

Abas M, Ali GC, Nakimuli-Mpungu E, Chibanda D. Depression in people living with HIV in sub-Saharan Africa: time to act. Trop Med Int Health. 2014;19:1392–6.PubMed

17.

Kingori C, Haile ZT, Ngatia P. Depression symptoms, social support and overall health among HIV-positive individuals in Kenya. Int J STD AIDS. 2015;26:165–72.PubMed

18.

Wroe EB, Hedt-Gauthier BL, Franke MF, Nsanzimana S, Turinimana JB, Drobac P. Depression and patterns of self-reported adherence to antiretroviral therapy in Rwanda. Int J STD AIDS. 2015;26:257–61.PubMed

19.

Memiah P, Shumba C, Etienne-Mesubi M, Agbor S, Hossain MB, Komba P, et al. The effect of depressive symptoms and CD4 count on adherence to highly active antiretroviral therapy in sub-Saharan Africa. J Int Assoc Provid AIDS Care. 2014;13:346–52.PubMed

20.

Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, et al. Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry. 2002;159:1752–9.PubMed

21.

Regan M, Muhihi A, Nagu T, Aboud S, Ulenga N, Kaaya S, et al. Depression and viral suppression among adults living with HIV in Tanzania. AIDS Behav. 2021;25:3097–105. https://doi.org/10.1007/s10461-021-03187-y.CrossRefPubMedPubMedCentral

22.

Sin NL, DiMatteo MR. Depression treatment enhances adherence to antiretroviral therapy: a meta-analysis. Ann Behav Med. 2014;47:259–69.PubMed

23.

Nel A, Kagee A. The relationship between depression, anxiety and medication adherence among patients receiving antiretroviral treatment in South Africa. AIDS Care. 2013;25:948–55.PubMed

24.

Nakimuli-Mpungu E, Musisi S, Wamala K, Okello J, Ndyanabangi S, Birungi J, et al. Effectiveness and cost-effectiveness of group support psychotherapy delivered by trained lay health workers for depression treatment among people with HIV in Uganda: a cluster-randomised trial. Lancet Glob Health. 2020;8:e387–98.PubMed

25.

Zhong H, Arjmand IK, Brandeau ML, Bendavid E. Health outcomes and cost-effectiveness of treating depression in people with HIV in Sub-Saharan Africa: a model-based analysis. AIDS Care. 2021;33:441–7.PubMed

26.

Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry. 2003;54:295–306.PubMed

27.

Nanni MG, Caruso R, Mitchell AJ, Meggiolaro E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015;17:1–11. https://doi.org/10.1007/s11920-014-0530-4.CrossRef

28.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.PubMedPubMedCentral

29.

Johnson N, Phillips M. Rayyan for systematic reviews. J Electron Resour Librariansh. 2018;30:46–8. https://doi.org/10.1080/1941126X.2018.1444339.CrossRef

30.

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73:712–6.PubMed

31.

Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Med Res Methodol. 2009;9:1–11. https://doi.org/10.1186/1471-2288-9-59.CrossRef

32.

Cochrane Training. Review manager [Internet]. [cited 2023 Aug 28]. Available from: https://training.cochrane.org/online-learning/core-software/revman.

33.

Cochrane Training. Chapter 10: analysing data and undertaking meta-analyses [Internet]. [cited 2023 Aug 28]. Available from: https://training.cochrane.org/handbook/current/chapter-10#section-10-4.

34.

Mavridis D, Salanti G. How to assess publication bias: funnel plot, trim-and-fill method and selection models. BMJ Ment Health. 2014;17:30–30.

35.

Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629.PubMedPubMedCentral

36.

Simmonds M. Quantifying the risk of error when interpreting funnel plots. Syst Rev. 2015;4:1–7. https://doi.org/10.1186/s13643-015-0004-8.CrossRef

37.

Anderson JC, Campbell JC, Glass NE, Decker MR, Perrin N, Farley J. Impact of intimate partner violence on clinic attendance, viral suppression and CD4 cell count of women living with HIV in an urban clinic setting. AIDS Care. 2018;30:399–408.PubMedPubMedCentral

38.

Chowdhury P, Beer L, Shouse R, Bradley H. Brief report: clinical outcomes of young black men receiving HIV medical care in the United States, 2009–2014. J Acquir Immune Defic Syndr. 2019;81:5–9.PubMedPubMedCentral

39.

Jain MK, Li X, Adams-Huet B, Tiruneh YM, Luque AE, Duarte P, et al. The risk of depression among racially diverse people living with HIV: the impact of HIV viral suppression. AIDS Care. 2021;33:645–53.PubMed

40.

Shacham E, Estlund AL, Tanner AE, Presti R. Challenges to HIV management among youth engaged in HIV care. AIDS Care. 2016;29:189–96. https://doi.org/10.1080/09540121.2016.1204422.CrossRefPubMed

41.

Solomon H, Linton SL, del Rio C, Hussen SA. Housing instability, depression, and HIV viral load among young black gay, bisexual, and other men who have sex with men in Atlanta, Georgia. J Assoc Nurses AIDS Care. 2020;31:219–27.PubMed

42.

Gokhale RH, Weiser J, Sullivan PS, Luo Q, Shu F, Bradley H. Depression prevalence, antidepressant treatment status, and association with sustained HIV viral suppression among adults living with HIV in care in the United States, 2009–2014. AIDS Behav. 2019;23:3452–9.PubMed

43.

Aibibula W, Cox J, Hamelin A, Moodie E, Anema A, Klein M, et al. Association between depressive symptoms, CD4 count and HIV viral suppression among HIV-HCV co-infected people. AIDS Care. 2018;30:643–9. https://doi.org/10.1080/09540121.2018.1431385.CrossRefPubMed

44.

Castel AD, Kalmin MM, Hart RLD, Young HA, Hays H, Benator D, et al. Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care—Washington, DC*. AIDS Care. 2016;28:1355–64.PubMedPubMedCentral

45.

Kassaye S, Wang C, Ocampo J, Wilson T, Anastos K, Cohen M, et al. Viremia trajectories of HIV in HIV-positive women in the United States, 1994–2017. JAMA Netw Open. 2019;2:e193822.PubMedPubMedCentral

46.

Kohn JN, Loop MS, Kim-Chang JJ, Garvie PA, Sleasman JW, Fischer B, et al. Trajectories of depressive symptoms, neurocognitive function, and viral suppression with antiretroviral therapy among youth with HIV over 36 months. J Acquir Immune Defic Syndr. 2021;87:851–9.PubMed

47.

Lesko C, Hutton H, Fojo A, Shen N, Moore R, Chander G. Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014–2019. AIDS. 2021; Available from: https://journals.lww.com/aidsonline/Fulltext/2021/10010/Depression_and_HIV_viral_nonsuppression_among.14.aspx/?cid=eTOC%20Issues.2021-aidsonline-00002030-202110010-00000&rid=V_0000000024530939&TargetID=&EjpToken=lQkB9CibvGpuwL94bY0oh8Iiyi4UJm_Sm8hMyBL4ZbVLubm9aTMI1DiAuAxwh45f7fLe-LZnbA&mkt_tok=NjgxLUZIRS00MjkAAAF_TKb412pGyy8ixQUmGUvdzd0QAhYdLRw2k9eML8y9AeiRiIx-zehWBM1h_myJ9NbOhNpODAilRaeqdh4x4dzw3uvvQL0EUllOk1NK4ZoSjELXWb1yng.

48.

Li MJ, Su E, Garland WH, Oksuzyan S, Lee SJ, Kao UH, et al. Trajectories of viral suppression in people living with HIV receiving coordinated care: differences by comorbidities. J Acquir Immune Defic Syndr. 2020;84:387–95.PubMedPubMedCentral

49.

McFall AM, Dowdy DW, Zelaya CE, Murphy K, Wilson TE, Young MA, et al. Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity. J Acquir Immune Defic Syndr. 2013;64:289–98.PubMed

50.

Momplaisir FM, Aaron E, Bossert L, Anderson E, Tatahmentan M, Okafor V, et al. HIV care continuum outcomes of pregnant women living with HIV with and without depression. AIDS Care. 2018;30:1580.PubMedPubMedCentral

51.

Spence AB, Michel K, Wang C, Dutton MA, Lee K, Merenstein D, et al. Viral suppression is associated with HIV treatment self-efficacy in a cohort of women in Washington, DC. AIDS Patient Care STDS. 2021;35:75–83. https://doi.org/10.1089/apc.2020.0224.CrossRefPubMedPubMedCentral

52.

Wilson TE, Kay ES, Turan B, Johnson MO, Kempf MC, Turan JM, et al. Healthcare empowerment and HIV viral control: mediating roles of adherence and retention in care. Am J Prev Med. 2018;54:756–64.PubMedPubMedCentral

53.

Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression—a systematic review of interventions. Psychol Health Med. 2011;16:493–527.PubMed

54.

Herbert TB, Cohen S. Depression and immunity: a meta-analytic review. Psychol Bull. 1993;113:472–86.PubMed

55.

Kronfol Z. Immune dysregulation in major depression: a critical review of existing evidence. Int J Neuropsychopharmacol. 2002;5:333–43.PubMed

56.

Goyal S, Srivastava K, Kodange C, Bhat PS. Immunological changes in depression. Ind Psychiatry J. 2017;26:201.PubMedPubMedCentral

57.

Bernard C, Dabis F, De Rekeneire N. Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2017;12:e0181960.PubMedPubMedCentral

58.

Nyirenda M, Chatterji S, Rochat T, Mutevedzi P, Newe ML. Prevalence and correlates of depression among HIV-infected and -affected older people in rural South Africa. J Affect Disord. 2013;151:31.PubMedPubMedCentral

59.

Obadeji A, Ogunlesi A, Adebowale T. Prevalence and predictors of depression in people living with HIV/AIDS attending an outpatient clinic in Nigeria. Iran J Psychiatry Behav Sci. 2014;8:26.PubMedPubMedCentral

60.

Sheehan DM, Dawit R, Gbadamosi SO, Fennie KP, Li T, Gebrezgi M, et al. Sustained HIV viral suppression among men who have sex with men in the Miami-Dade County Ryan White Program: the effect of demographic, psychosocial, provider and neighborhood factors. BMC Public Health. 2020;20:1–12. https://doi.org/10.1186/s12889-020-8442-1.CrossRef

61.

O’Cleirigh C, Pantalone DW, Batchelder AW, Hatzenbuehler ML, Marquez SM, Grasso C, et al. Co-occurring psychosocial problems predict HIV status and increased health care costs and utilization among sexual minority men. J Behav Med. 2018;41:450–7. https://doi.org/10.1007/s10865-018-9913-z.CrossRefPubMedPubMedCentral

62.

HIV.gov. When undetectable is unachievable: study offers insights into HIV persistence [Internet]. 2019 [cited 2024 Oct 5]. Available from: https://www.hiv.gov/blog/when-undetectable-unachievable-study-offers-insights-hiv-persistence.

63.

Prabhu S, McFall AM, Mehta SH, Srikrishnan AK, Kumar MS, Anand S, et al. Psychosocial barriers to viral suppression in a community-based sample of Human Immunodeficiency Virus–infected men who have sex with men and people who inject drugs in India. Clin Infect Dis. 2020;70:304–13. https://doi.org/10.1093/cid/ciz175.CrossRefPubMed

64.

Abler L, Sikkema KJ, Watt MH, Hansen NB, Wilson PA, Kochman A. Depression and HIV serostatus disclosure to sexual partners among newly HIV-diagnosed men who have sex with men. AIDS Patient Care STDS. 2015;29:550–8. https://doi.org/10.1089/apc.2015.0122.CrossRefPubMedPubMedCentral

65.

Goldstein ZG. Overview of factors associated with HIV viral load suppression in transgender women. J Appl Lab Med. 2021;6:257–63.PubMed

66.

Herbst JH, Jacobs ED, Finlayson TJ, McKleroy VS, Neumann MS, Crepaz N. Estimating HIV prevalence and risk behaviors of transgender persons in the United States: a systematic review. AIDS Behav. 2008;12:1–17.PubMed

67.

Havlik RJ, Brennan M, Karpiak SE, Havlik RJ, Brennan M, Karpiak SE. Comorbidities and depression in older adults with HIV. Sex Health. 2011;8:551–9.PubMed

68.

Psaros C, Geller PA, Aaron E. The importance of identifying and treating depression in HIV infected, pregnant women: a review. J Psychosom Obstet Gynaecol. 2009;30:275–81. https://doi.org/10.3109/01674820903254740.CrossRefPubMed

69.

Brown LK, Kennard BD, Emslie GJ, Mayes TL, Whiteley LB, Bethel J, et al. Effective treatment of depressive disorders in medical clinics for adolescents and young adults living with HIV: a controlled trial. J Acquir Immune Defic Syndr. 2016;71:38–46.PubMedPubMedCentral

70.

Menza TW, Choi SK, LeGrand S, Muessig K, Hightow-Weidman L. Correlates of self-reported viral suppression among HIV-positive, young, black men who have sex with men participating in a randomized controlled trial of an internet-based HIV prevention intervention. Sex Transm Dis. 2018;45:118–26.PubMedPubMedCentral

71.

Momplaisir F, Hussein M, Kacanek D, Brady K, Agwu A, Scott G, et al. Perinatal depressive symptoms, Human Immunodeficiency Virus (HIV) suppression, and the underlying role of antiretroviral therapy adherence: a longitudinal mediation analysis in the IMPAACT P1025 cohort. Clin Infect Dis. 2021;73:1379–87.PubMedPubMedCentral

72.

Robbins GK, Cohn SE, Harrison LJ, Smeaton L, Moran L, Rusin D, et al. Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251. HIV Clin Trials. 2016;17:165–72.PubMedPubMedCentral

73.

Diepstra K, Lu H, McManus KA, Rogawski McQuade ET, Rhodes AG, Westreich D. What we talk about when we talk about durable viral suppression. AIDS. 2020;34:1683.PubMed

Title: Depressive Symptoms and HIV Viral Suppression: A Systematic Review and Meta-analysis
Authors: Bishan Huang
Alitasha Younger
Mary P. Gallant
Thomas J. O’Grady
Publication date: 18-12-2024
Publisher: Springer US
Keyword: Human Immunodeficiency Virus
Published in: AIDS and Behavior / Issue 3/2025
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-024-04571-0

Risk Factors for Viral Non-suppression Among Youth Living with HIV in Nigeria: Findings from the iCARE Nigeria Study

Human Immunodeficiency Virus
Original Paper

Causal Effects of Alcohol Consumption on Condom Negotiation Skills of Women with Varying Sexual Assault Histories

Human Immunodeficiency Virus
Original Paper

Randomized Pilot Trial of the Text-Based Adherence Game for Ghanaian Youth with HIV

Human Immunodeficiency Virus
Original Paper

Evaluation of an HIV-related Education Intervention Scale-up: A Hybrid Type 3 Effectiveness-implementation Study in the Dominican Republic

Human Immunodeficiency Virus
Original Paper

Infection and Persistent Infection of Human Papillomavirus Among HIV-Negative Men Who Have Sex with Men in Xinjiang, China: A Prospective Cohort Study

Human Papillomavirus
Original Paper

HIV Support Group Care Utilization and its Effect on Treatment Outcome Among HIV Patients on Antiretroviral Therapy: Evidence from Ethiopia Population-Based HIV Impact Assessment

Human Immunodeficiency Virus
Original Paper

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now

Podcast | Sexual health in older age

Springer Medicine

Depressive Symptoms and HIV Viral Suppression: A Systematic Review and Meta-analysis

Abstract

Other articles of this Issue 3/2025

Risk Factors for Viral Non-suppression Among Youth Living with HIV in Nigeria: Findings from the iCARE Nigeria Study

Causal Effects of Alcohol Consumption on Condom Negotiation Skills of Women with Varying Sexual Assault Histories

Randomized Pilot Trial of the Text-Based Adherence Game for Ghanaian Youth with HIV

Evaluation of an HIV-related Education Intervention Scale-up: A Hybrid Type 3 Effectiveness-implementation Study in the Dominican Republic

Infection and Persistent Infection of Human Papillomavirus Among HIV-Negative Men Who Have Sex with Men in Xinjiang, China: A Prospective Cohort Study

HIV Support Group Care Utilization and its Effect on Treatment Outcome Among HIV Patients on Antiretroviral Therapy: Evidence from Ethiopia Population-Based HIV Impact Assessment

Elevate your expertise in aplastic anemia (Link opens in a new window)

Keynote series | Spotlight on menopause

Podcast | Sexual health in older age

Springer Medicine

Abstract

Please log in to get access to this content